Tags

Type your tag names separated by a space and hit enter

Efficacy of famotidine and omeprazole in healing symptoms of non-erosive gastro-oesophageal reflux disease: randomized-controlled study of gastro-oesophageal reflux disease.
Aliment Pharmacol Ther. 2005 Jun; 21 Suppl 2:2-9.AP

Abstract

BACKGROUND

The epidemiology and pathophysiology of non-erosive gastro-oesophageal reflux disease differs from erosive gastro-oesophageal reflux disease. There is a possibility that non-erosive gastro-oesophageal reflux disease treatment requires a different regimen/approach but it is not yet acknowledged.

AIM

To investigate the efficacy of famotidine and omeprazole in the treatment of gastro-oesophageal reflux disease, especially non-erosive gastro-oesophageal reflux disease.

PATIENTS AND METHODS

A randomized, open-label trial was conducted. Fifty-four gastro-oesophageal reflux disease patients were assigned to treatment with famotidine at a dosage of 20 mg twice daily; or omeprazole, 20 mg once daily, for a period of 8 weeks. The Short Form-36 Health Survey and Gastrointestinal Symptom Rating Scale administered at baseline and after 8 weeks of treatment as well as a symptom questionnaire were conducted daily.

RESULTS

Short Form-36 revealed that gastro-oesophageal reflux disease has severe impact on health-related quality of life. Thirty-nine subjects (77%) were endoscopically diagnosed as non-erosive gastro-oesophageal reflux disease. The mean Gastrointestinal Symptom Rating Scale abdominal pain, and indigestion score of non-erosive gastro-oesophageal reflux disease significantly improved in famotidine-treated patients (P < 0.05), but not in the omeprazole. There was no significant change regarding improved heartburn symptoms of non-erosive gastro-oesophageal reflux disease between treatments in the daytime or night-time.

CONCLUSION

Famotidine and omeprazole were both effective in improving symptoms of gastro-oesophageal reflux disease, particularly non-erosive gastro-oesophageal reflux disease.

Authors+Show Affiliations

Department of Internal Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

15943840

Citation

Wada, T, et al. "Efficacy of Famotidine and Omeprazole in Healing Symptoms of Non-erosive Gastro-oesophageal Reflux Disease: Randomized-controlled Study of Gastro-oesophageal Reflux Disease." Alimentary Pharmacology & Therapeutics, vol. 21 Suppl 2, 2005, pp. 2-9.
Wada T, Sasaki M, Kataoka H, et al. Efficacy of famotidine and omeprazole in healing symptoms of non-erosive gastro-oesophageal reflux disease: randomized-controlled study of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2005;21 Suppl 2:2-9.
Wada, T., Sasaki, M., Kataoka, H., Tanida, S., Itoh, K., Ogasawara, N., Oshima, T., Togawa, S., Kubota, E., Yamada, T., Mori, Y., Fujita, F., Ohara, H., Nakao, H., Sobue, S., Joh, T., & Itoh, M. (2005). Efficacy of famotidine and omeprazole in healing symptoms of non-erosive gastro-oesophageal reflux disease: randomized-controlled study of gastro-oesophageal reflux disease. Alimentary Pharmacology & Therapeutics, 21 Suppl 2, 2-9.
Wada T, et al. Efficacy of Famotidine and Omeprazole in Healing Symptoms of Non-erosive Gastro-oesophageal Reflux Disease: Randomized-controlled Study of Gastro-oesophageal Reflux Disease. Aliment Pharmacol Ther. 2005;21 Suppl 2:2-9. PubMed PMID: 15943840.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Efficacy of famotidine and omeprazole in healing symptoms of non-erosive gastro-oesophageal reflux disease: randomized-controlled study of gastro-oesophageal reflux disease. AU - Wada,T, AU - Sasaki,M, AU - Kataoka,H, AU - Tanida,S, AU - Itoh,K, AU - Ogasawara,N, AU - Oshima,T, AU - Togawa,S, AU - Kubota,E, AU - Yamada,T, AU - Mori,Y, AU - Fujita,F, AU - Ohara,H, AU - Nakao,H, AU - Sobue,S, AU - Joh,T, AU - Itoh,M, PY - 2005/6/10/pubmed PY - 2005/8/16/medline PY - 2005/6/10/entrez SP - 2 EP - 9 JF - Alimentary pharmacology & therapeutics JO - Aliment. Pharmacol. Ther. VL - 21 Suppl 2 N2 - BACKGROUND: The epidemiology and pathophysiology of non-erosive gastro-oesophageal reflux disease differs from erosive gastro-oesophageal reflux disease. There is a possibility that non-erosive gastro-oesophageal reflux disease treatment requires a different regimen/approach but it is not yet acknowledged. AIM: To investigate the efficacy of famotidine and omeprazole in the treatment of gastro-oesophageal reflux disease, especially non-erosive gastro-oesophageal reflux disease. PATIENTS AND METHODS: A randomized, open-label trial was conducted. Fifty-four gastro-oesophageal reflux disease patients were assigned to treatment with famotidine at a dosage of 20 mg twice daily; or omeprazole, 20 mg once daily, for a period of 8 weeks. The Short Form-36 Health Survey and Gastrointestinal Symptom Rating Scale administered at baseline and after 8 weeks of treatment as well as a symptom questionnaire were conducted daily. RESULTS: Short Form-36 revealed that gastro-oesophageal reflux disease has severe impact on health-related quality of life. Thirty-nine subjects (77%) were endoscopically diagnosed as non-erosive gastro-oesophageal reflux disease. The mean Gastrointestinal Symptom Rating Scale abdominal pain, and indigestion score of non-erosive gastro-oesophageal reflux disease significantly improved in famotidine-treated patients (P < 0.05), but not in the omeprazole. There was no significant change regarding improved heartburn symptoms of non-erosive gastro-oesophageal reflux disease between treatments in the daytime or night-time. CONCLUSION: Famotidine and omeprazole were both effective in improving symptoms of gastro-oesophageal reflux disease, particularly non-erosive gastro-oesophageal reflux disease. SN - 0269-2813 UR - https://www.unboundmedicine.com/medline/citation/15943840/Efficacy_of_famotidine_and_omeprazole_in_healing_symptoms_of_non_erosive_gastro_oesophageal_reflux_disease:_randomized_controlled_study_of_gastro_oesophageal_reflux_disease_ L2 - https://doi.org/10.1111/j.1365-2036.2005.02467.x DB - PRIME DP - Unbound Medicine ER -